Executives On The Move: Five Prime Fills Its CFO Slot, Myovant Appoints Chief Commercial Officer and Onconova Adds a CMO, R&D
Executive Summary
Immuno-oncology treatment developer Five Prime Therapeutics hires a CFO, while Myovant Sciences, focused on women’s health and endocrine disease, appoints a chief commercial officer. And Onconova Therapeutics boosts its drug development expertise with addition of new CMO, R&D.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: New Hires At Everest Medicines, Arvinas, Fulcrum Therapeutics And More
Recent executive changes in the industry include seven new chief medical officers, and new chief commercial officers at Adaptimmune Therapeutics and Syndax Pharmaceuticals.